Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1982 Oct;38(1):251–259. doi: 10.1128/iai.38.1.251-259.1982

Cytotoxic Effector Cells from Infectious Mononucleosis Patients in the Acute Phase Do Not Specifically Kill Epstein-Barr Virus Genome-Carrying Lymphoid Cell Lines

Pravin C Patel 1, Guérin Dorval 2, José Menezes 1
PMCID: PMC347726  PMID: 6292093

Abstract

We describe a study in which we investigated the cytotoxic activities of thymusderived (T) lymphocytes and natural killer cells against Epstein-Barr virus (EBV) genome-carrying lymphoid cell lines. Purified subpopulations of lymphocytes from eight patients with infectious mononucleosis and six healthy normal EBV-seropositive donors were tested. Enriched T-cells were obtained by passing purified whole blood lymphocyte preparations through human immunoglobulin-anti-immunoglobulin-coated glass bead columns. The cytolytic activity of effector cells was determined by the ability of these cells to lyse human target cells that were internally labeled with 51Cr. These targets included cells from both EBV genome-carrying and EBV genome-negative lymphoid lines derived from malignant tumors, as well as from lymphocytes transformed in vitro by EBV, and were chosen to represent a wide spectrum of EBV-associated membrane antigens. We found that cytotoxic T-cells from patients with infectious mononucleosis showed no EBV-related specific cell killing per se, although a trend for increased killing of cell lines derived from spontaneous in vivo growing tumors, EBV genome carrying or not, was noted; however, this trend was not observed with cell lines derived from cord blood lymphocytes after EBV infection in vitro. In addition, our data suggest that natural killer cells may play an important role in controlling EBV infection in patients with infectious mononucleosis in the acute phase of the disease, particularly since T-cells (obtained after removal on immunoglobulin-anti-immunoglobulin columns of natural killer cells presumably bearing Fc receptors) were less efficient killers than whole blood lymphocytes; furthermore, lysis by whole blood lymphocytes was also greatest against cell lines derived from malignant tumors (as opposed to in vitro EBV-transformed cord blood lymphoid lines), irrespective of whether these targets were EBV genome positive or negative.

Full text

PDF
251

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakacs T., Svedmyr E., Klein E. EBV-related cytotoxicity of Fc receptor negative T lymphocytes separated from the blood of infectious mononucleosis patients. Cancer Lett. 1978 Apr;4(4):185–189. doi: 10.1016/s0304-3835(78)94347-1. [DOI] [PubMed] [Google Scholar]
  2. Blazar B., Patarroyo M., Klein E., Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med. 1980 Mar 1;151(3):614–627. doi: 10.1084/jem.151.3.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crawford D. H., Rickinson A. B., Finerty S., Epstein M. A. Epstein-Barr (EB) virus genome-containing, EB nuclear antigen-negative B-lymphocyte populations in blood in acute infectious mononucleosis. J Gen Virol. 1978 Mar;38(3):449–460. doi: 10.1099/0022-1317-38-3-449. [DOI] [PubMed] [Google Scholar]
  4. Diehl V., Henle G., Henle W., Kohn G. Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol. 1968 Jul;2(7):663–669. doi: 10.1128/jvi.2.7.663-669.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dorval G., Welsh K. I., Nilsson K., Wigzell H. Quantitation of beta2-microglobulin and HLA on the surface of human cells. I. T and B lymphocytes and lymphoblasts. Scand J Immunol. 1977;6(4):255–263. doi: 10.1111/j.1365-3083.1977.tb00392.x. [DOI] [PubMed] [Google Scholar]
  6. Dorval G., Welsh K. I., Wigzell H. A radioimmunoassay of cellular surface antigens on living cells using iodinated soluble protein A from Staphylococcus aureus. J Immunol Methods. 1975 Jun;7(2-3):237–250. doi: 10.1016/0022-1759(75)90021-6. [DOI] [PubMed] [Google Scholar]
  7. Dorval G., Wigzell H., Leibold W., Killander D. Analysis of cell-surface markers with staphylococcal protein A: fluorescence studies on mammalian lymphoid determinants. J Immunol Methods. 1976;9(3-4):251–266. doi: 10.1016/0022-1759(76)90200-3. [DOI] [PubMed] [Google Scholar]
  8. Epstein M. A., Achong B. G. Recent progress in Epstein-Barr virus research. Annu Rev Microbiol. 1977;31:421–445. doi: 10.1146/annurev.mi.31.100177.002225. [DOI] [PubMed] [Google Scholar]
  9. Fresen K. O., Hausen H. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains. Int J Cancer. 1976 Feb 15;17(2):161–166. doi: 10.1002/ijc.2910170203. [DOI] [PubMed] [Google Scholar]
  10. Golstein P., Blomgren H. Further evidence for autonomy of T cells mediating specific in vitro cytotoxicity: efficiency of very small amounts of highly purified T cells. Cell Immunol. 1973 Oct;9(1):127–141. doi: 10.1016/0008-8749(73)90174-3. [DOI] [PubMed] [Google Scholar]
  11. Herberman R. B., Oldham R. K. Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. J Natl Cancer Inst. 1975 Oct;55(4):749–753. doi: 10.1093/jnci/55.4.749. [DOI] [PubMed] [Google Scholar]
  12. Hinuma Y., Grace J. T., Jr Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures. Proc Soc Exp Biol Med. 1967 Jan;124(1):107–111. doi: 10.3181/00379727-124-31677. [DOI] [PubMed] [Google Scholar]
  13. Hutt-Fletcher L. M., Gilbert C. J. Cytotoxic cells induced in vitro by Epstein-Barr Virus antigens. Cell Immunol. 1981 Sep 1;63(1):91–105. doi: 10.1016/0008-8749(81)90031-9. [DOI] [PubMed] [Google Scholar]
  14. Hutt L. M., Huang Y. T., Dascomb H. E., Pagano J. S. Enhanced destruction of lymphoid cell lines by peripheral blood leukocytes taken from patients with acute infectious mononucleosis. J Immunol. 1975 Jul;115(1):243–248. [PubMed] [Google Scholar]
  15. Jondal M., Holm G., Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972 Aug 1;136(2):207–215. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jondal M., Spine C., Targan S. Human spontaneous killer cells selective for tumour-derived target cells. Nature. 1978 Mar 2;272(5648):62–64. doi: 10.1038/272062a0. [DOI] [PubMed] [Google Scholar]
  17. Jondal M. Surface markers on human B and T lymphocytes. IV. Distribution of surface markers on resting and blast-transformed lymphocytes. Scand J Immunol. 1974;3(6):739–747. doi: 10.1111/j.1365-3083.1974.tb01309.x. [DOI] [PubMed] [Google Scholar]
  18. Klein E., Ernberg I., Masucci M. G., Szigeti R., Wu Y. T., Masucci G., Svedmyr E. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis. Cancer Res. 1981 Nov;41(11 Pt 1):4210–4215. [PubMed] [Google Scholar]
  19. Klein G., Svedmyr E., Jondal M., Persson P. O. EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer. 1976 Jan 15;17(1):21–26. doi: 10.1002/ijc.2910170105. [DOI] [PubMed] [Google Scholar]
  20. Klein G. The Epstein-Barr virus and neoplasia. N Engl J Med. 1975 Dec 25;293(26):1353–1357. doi: 10.1056/NEJM197512252932607. [DOI] [PubMed] [Google Scholar]
  21. Lozzio C. B., Lozzio B. B. Cytotoxicity of a factor isolated from human spleen. J Natl Cancer Inst. 1973 Feb;50(2):535–538. doi: 10.1093/jnci/50.2.535. [DOI] [PubMed] [Google Scholar]
  22. Menezes J., Leibold W., Klein G. Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res. 1975 May;92(2):478–484. doi: 10.1016/0014-4827(75)90404-8. [DOI] [PubMed] [Google Scholar]
  23. Menezes J., Leibold W., Klein G., Clements G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine. 1975 Jul;22(4):276–284. [PubMed] [Google Scholar]
  24. Miller G., Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A. 1973 Jan;70(1):190–194. doi: 10.1073/pnas.70.1.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Minowada J., Janossy G., Greaves M. F., Tsubota T., Srivastava B. I., Morikawa S., Tatsumi E. Expression of an antigen associated with acute lymphoblastic leukemia in human leukemia-lymphoma cell lines. J Natl Cancer Inst. 1978 Jun;60(6):1269–1277. doi: 10.1093/jnci/60.6.1269. [DOI] [PubMed] [Google Scholar]
  26. Minowada J., Klein G., Clifford P., Klein E., Moore G. E. Studies of Burkitt lymphoma cells. I. Establishment of a cell line (B35M) and its characteristics. Cancer. 1967 Sep;20(9):1430–1437. doi: 10.1002/1097-0142(196709)20:9<1430::aid-cncr2820200909>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  27. Mogensen C. E. The glomerular permeability determined by dextran clearance using Sephadex gel filtration. Scand J Clin Lab Invest. 1968;21(1):77–82. doi: 10.3109/00365516809076979. [DOI] [PubMed] [Google Scholar]
  28. Nilsson K., Pontén J. Classification and biological nature of established human hematopoietic cell lines. Int J Cancer. 1975 Feb 15;15(2):321–341. doi: 10.1002/ijc.2910150217. [DOI] [PubMed] [Google Scholar]
  29. Osborn D. C., Fox R. A., Fernandez L. A., MacSween J. M., Langley G. R. Cytotoxic lymphocytes in infectious mononucleosis. Can Med Assoc J. 1976 Dec 4;115(11):1118–1119. [PMC free article] [PubMed] [Google Scholar]
  30. PULVERTAFT J. V. A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol. 1965 May;18:261–273. doi: 10.1136/jcp.18.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Patel P. C., Menezes J., Bourkas A., Dorval G., Rivard G. E., Boulay G., Stanley P., Joncas J. H. Rosette formation by human lymphoid cells with monkey red blood cells. Ann Immunol (Paris) 1978 Apr-Jun;129 100(4):449–462. [PubMed] [Google Scholar]
  32. Patel P. C., Menezes J. Epstein-Barr virus (EBV)--lymphoid cell interactions. II. The influence of the EBV replication cycle on natural killing and antibody-dependent cellular cytotoxicity against EBV-infected cells. Clin Exp Immunol. 1982 Jun;48(3):589–601. [PMC free article] [PubMed] [Google Scholar]
  33. Pross H. F., Baines M. G., Jondal M. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. II. Is the complement receptor necessarily present on the killer cells? Int J Cancer. 1977 Sep 15;20(3):353–358. doi: 10.1002/ijc.2910200306. [DOI] [PubMed] [Google Scholar]
  34. Quinnan G. V., Manischewitz J. E. The role of natural killer cells and antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection. J Exp Med. 1979 Dec 1;150(6):1549–1554. doi: 10.1084/jem.150.6.1549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  36. Rickinson A. B., Epstein M. A., Crawford D. H. Absence of infectious Epstein-Barr virus in blood in acute infectious mononucleosis. Nature. 1975 Nov 20;258(5532):236–236. doi: 10.1038/258236a0. [DOI] [PubMed] [Google Scholar]
  37. Rickinson A. B., Moss D. J., Wallace L. E., Rowe M., Misko I. S., Epstein M. A., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res. 1981 Nov;41(11 Pt 1):4216–4221. [PubMed] [Google Scholar]
  38. Royston I., Sullivan J. L., Periman P. O., Perlin E. Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N Engl J Med. 1975 Dec 4;293(23):1159–1163. doi: 10.1056/NEJM197512042932301. [DOI] [PubMed] [Google Scholar]
  39. Seeley J., Svedmyr E., Weiland O., Klein G., Moller E., Eriksson E., Andersson K., van der Waal L. Epstein Barr virus selective T cells in infectious mononucleosis are not restricted to HLA-A and B antigens. J Immunol. 1981 Jul;127(1):293–300. [PubMed] [Google Scholar]
  40. Shope T. C., Kaplan J. Inhibition of the in vitro outgrowth of Epstein-Barr virus-infected lymphocytes by TG lymphocytes. J Immunol. 1979 Nov;123(5):2150–2155. [PubMed] [Google Scholar]
  41. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Viallat J., Svedmyr E., Steinitz M., Klein G. Stimulation of peripheral human lymphocytes by autologous EBV genome-carrying lymphoblastoid cell lines. Cell Immunol. 1978 Jun;38(1):68–75. doi: 10.1016/0008-8749(78)90032-1. [DOI] [PubMed] [Google Scholar]
  43. West W. H., Cannon G. B., Kay H. D., Bonnard G. D., Herberman R. B. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol. 1977 Jan;118(1):355–361. [PubMed] [Google Scholar]
  44. Wigzell H., Sundqvist K. G., Yoshida T. O. Separation of cells according to surface antigens by the use of antibody-coated columns. Fractionation of cells carrying immunoglobulins and blood group antigen. Scand J Immunol. 1972;1(1):75–87. doi: 10.1111/j.1365-3083.1972.tb03737.x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES